scispace - formally typeset
H

Hilary Longhurst

Researcher at Barts Health NHS Trust

Publications -  114
Citations -  6356

Hilary Longhurst is an academic researcher from Barts Health NHS Trust. The author has contributed to research in topics: Hereditary angioedema & Angioedema. The author has an hindex of 32, co-authored 95 publications receiving 5316 citations. Previous affiliations of Hilary Longhurst include National Health Service & Queen Mary University of London.

Papers
More filters
Journal ArticleDOI

Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

TL;DR: This supplement contains work presented at the third workshop and expanded content toward a definitive picture of angioedema in the absence of allergy, and includes cumulative genetic investigations; multinational laboratory diagnosis recommendations; current pathogenesis hypotheses; and suggested prophylaxis and acute attack treatment.
Journal ArticleDOI

2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema

Tom Bowen, +59 more
TL;DR: Consensus approach is only an interim guide to a complex disorder such as HAE and should be replaced as soon as possible with large phase III and IV clinical trials, meta analyses, and using data base registry validation of approaches.
Journal ArticleDOI

Clinical picture and treatment of 2212 patients with common variable immunodeficiency

TL;DR: In this article, the authors analyzed the clinical presentation, association between clinical features, and differences and effects of immunoglobulin treatment in Europe for Common Variable Immunodeficiency (CVID) patients.
Journal ArticleDOI

Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.

Tanya I. Coulter, +57 more
TL;DR: The severity of complications in some patients supports consideration of hematopoietic stem cell transplantation for severe childhood disease and clinical trials of selective PI3K&dgr; inhibitors offer new prospects for APDS treatment.